Skip to main content

Rybrevant Side Effects

Generic name: amivantamab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Aug 6, 2022.

Note: This document contains side effect information about amivantamab. Some dosage forms listed on this page may not apply to the brand name Rybrevant.

Applies to amivantamab: intravenous solution.

Serious side effects of Rybrevant

Along with its needed effects, amivantamab (the active ingredient contained in Rybrevant) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking amivantamab:

More common

  • Back pain
  • bleeding gums
  • blistering, crusting, irritation, itching, or reddening of the skin
  • blood in the urine
  • bloody nose
  • burning, crawling, itching, numbness, painful, prickling, "pins and needles", or tingling feelings
  • chest pain or tightness
  • chills
  • cough
  • coughing or spitting up blood
  • cracked, dry, or scaly skin
  • dry, itching skin
  • fever
  • flushing
  • headache
  • loosening of the fingernails
  • muscle or bone pain
  • nausea and vomiting
  • nerve pain
  • rash with flat lesions or small raised lesions on the skin
  • redness or soreness around the fingernails
  • sneezing
  • swelling
  • trouble breathing
  • unsteadiness or awkwardness
  • weakness in the arms, hands, legs, or feet

Less common

Rare

  • Blistering, peeling, or loosening of the skin
  • blurred vision or other change in vision
  • diarrhea
  • eye redness, irritation, or pain
  • red irritated eyes
  • red skin lesions, often with a purple center
  • sensitivity of the eye to light
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • tearing
  • unusual tiredness or weakness

Other side effects of Rybrevant

Some side effects of amivantamab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Canker sores
  • chapped, red, or swollen lips
  • constipation
  • decreased appetite
  • difficulty in moving
  • lack or loss of strength
  • muscle aches, cramps, or stiffness
  • pain in the arms or legs
  • pain in the joints
  • redness, swelling, or soreness of the tongue
  • scaling, redness, burning, pain, or other signs of inflammation of the lips
  • stomach pain
  • swelling or inflammation of the mouth

For Healthcare Professionals

Applies to amivantamab: intravenous solution.

Hematologic

Very common (10% or more): Lymphocytes decreased (36%), hemorrhage (e.g., epistaxis, gingival bleeding, hematuria, hemoptysis, hemorrhage, mouth hemorrhage, mucosal hemorrhage) (19%)[Ref]

Immunologic

Frequency not reported: Immunogenicity[Ref]

Local

Very common (10% or more): Infusion-related reactions (IRRs) (66[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (e.g., arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, neck pain, noncardiac chest pain, pain in extremity, spinal pain) (47%)[Ref]

Ocular

Uncommon (0.1% to 1%): Ocular toxicity (e.g., keratitis, uveitis)[Ref]

Metabolic

Very common (10% or more): Albumin decreased (79%), glucose increased (56%), phosphate decreased (33%), magnesium decreased (27%), sodium decreased (27%), potassium decreased (26%), anorexia (15%)[Ref]

Hepatic

Very common (10% or more): Alkaline phosphatase (ALP) increased (53%), alanine aminotransferase (ALT} increased (38%), aspartate aminotransferase (AST) increased (33%), gamma-glutamyl transferase (GGT) increased (27%)[Ref]

Respiratory

Very common (10% or more): Dyspnea/exertional dyspnea (37%), cough (e.g., cough, productive cough, upper airway cough syndrome) (25%), pneumonia (e.g., atypical pneumonia, lower respiratory tract infection, pneumonia, pneumonia aspiration, pulmonary sepsis) (10%)[Ref]

Other

Very common (10% or more): Fatigue/asthenia (33%), edema (e.g., eyelid edema, face edema, generalized edema, lip edema, edema, edema peripheral, periorbital edema, peripheral swelling) (27%), pyrexia (13%)

Uncommon (0.1% to 1%): Keratitis, uveitis[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (e.g., hypoesthesia, neuralgia, paresthesia, peripheral sensory neuropathy) (13%), dizziness (12%), headache/migraine (10%)[Ref]

Renal

Very common (10% or more): Creatinine increased (46%)[Ref]

Dermatologic

Very common (10% or more): Rash (e.g., acne, dermatitis, dermatitis acneiform, eczema, eczema asteatotic, palmar-plantar erythrodysesthesia syndrome, perineal rash, rash, rash erythematous, rash maculopapular, rash papular, rash vesicular, skin exfoliation, toxic epidermal necrolysis [TEN]) (84%), paronychia (50%), pruritus (18%), dry skin (14%)[Ref]

Gastrointestinal

Very common (10% or more): Nausea (36%), stomatitis (e.g., aphthous ulcer, cheilitis, glossitis, mouth ulceration, mucosal inflammation, pharyngeal inflammation, stomatitis) (26%), constipation (23%), diarrhea (16%), abdominal pain (e.g., abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, epigastric discomfort) (11%)[Ref]

Frequently asked questions

References

1. "Product Information. Rybrevant (amivantamab)." Janssen Biotech, Inc. (2021):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.